Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN V versus ACTICLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN V versus ACTICLATE.
ACHROMYCIN V vs ACTICLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-tRNA binding to mRNA-ribosome complex.
Inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), thereby increasing intestinal absorption and decreasing clearance of substrates; also inhibits CYP3A4 isoenzymes, reducing metabolism of CYP3A4 substrates.
250-500 mg orally every 6 hours
100 mg orally twice daily (12 hours apart) on an empty stomach (1 hour before or 2 hours after meals). Avoid milk, antacids, iron, calcium, magnesium, and zinc within 2 hours of administration.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Terminal elimination half-life is approximately 18-22 hours in patients with normal renal function; prolonged to 30-50 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Renal excretion of unchanged drug accounts for approximately 60% of the dose; fecal elimination via biliary secretion contributes about 30%; minor metabolism (<10%) produces inactive metabolites.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic